Xero Limited – Strategic Acquisition of Hubdoc


Xero Limited (ASX: XRO) announced the acquisition of Hubdoc for the consideration of US$ 70 Mn in which the transaction will be paid in two stages, with the initial purchase price of US$60 Mn consisting of 35 per cent in cash and 65 per cent in Xero equity. However, the group has already arranged new debt funding for the cash component of the aforesaid deal while the rest payment of US$10 Mn in equity will be issued to Hubdoc’s shareholders within 18 months and this will be subject to meet the agreed operational targets and conditions. The first tranche of equity will be issued based on a five trading-day Volume Weighted Average Price (VWAP) ending 30 July 2018, and the second tranche will be issued based on a five trading-day VWAP at the time of issue.

Hubdoc was incorporated in 2011, headquartered in Toronto, Canada. It provides data capture solution to its customers that helps accountants, bookkeepers, and small businesses to simplify administrative works like financial document collection and data entry. Currently, Hubdoc has a strong footprint in the US, Canada, UK, and Australia.

[optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

As per the arrangement, Hubdoc will keep on operating its business as on stand-alone basis within the XERO premises. Moreover, it will keep on being sold independently and will stay accessible to non-Xero clients, yet after some time it will be incorporated more deeply into the Xero platform and servicing customers globally. However, Xero will remain fully dedicated to its open ecosystem strategy and its customers will keep on having full access to in excess of 700 apps that connect with Xero.

With this news, the stock climbed up 3.5 per cent to $44.310 with the market-cap of circa $5.96 bn as on August 01, 2018 (AEST: 3:30 P.M.).

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report